Windlas Biotech Limited (WINDLAS) - Total Liabilities

Latest as of September 2025: Rs2.80 Billion INR ≈ $30.29 Million USD

Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has total liabilities worth Rs2.80 Billion INR (≈ $30.29 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore WINDLAS net asset momentum to track the company's year-over-year net asset growth rate.

Windlas Biotech Limited - Total Liabilities Trend (2018–2025)

This chart illustrates how Windlas Biotech Limited's total liabilities have evolved over time, based on quarterly financial data.

Windlas Biotech Limited Competitors by Total Liabilities

The table below lists competitors of Windlas Biotech Limited ranked by their total liabilities.

Company	Country	Total Liabilities
LVMC Holdings KO:900140	Korea	₩196.53 Billion
Catella AB (publ) ST:CAT-B	Sweden	Skr2.18 Billion
IM Vinaria Purcari SRL RO:WINE	Romania	RON437.36 Million
FREYR Battery SA NYSE:FREY	USA	$1.18 Billion
Tachan Securities Co Ltd TWO:6020	Taiwan	NT$3.02 Billion
Ultra Chip TWO:3141	Taiwan	NT$1.28 Billion
Kumpulan Fima Bhd KLSE:6491	Malaysia	RM599.89 Million
Tai-Saw Technology Co Ltd TWO:3221	Taiwan	NT$934.10 Million

Liability Composition Analysis (2018–2025)

This chart breaks down Windlas Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see WINDLAS market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.06	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.52	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.34	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Windlas Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Windlas Biotech Limited (2018–2025)

The table below shows the annual total liabilities of Windlas Biotech Limited from 2018 to 2025.

Year	Total Liabilities	Change
2025-03-31	Rs2.55 Billion ≈ $27.54 Million	+44.48%
2024-03-31	Rs1.76 Billion ≈ $19.06 Million	+39.12%
2023-03-31	Rs1.27 Billion ≈ $13.70 Million	+31.66%
2022-03-31	Rs962.33 Million ≈ $10.41 Million	-0.79%
2021-03-31	Rs970.04 Million ≈ $10.49 Million	-24.70%
2020-03-31	Rs1.29 Billion ≈ $13.93 Million	+23.17%
2019-03-31	Rs1.05 Billion ≈ $11.31 Million	-36.55%
2018-03-31	Rs1.65 Billion ≈ $17.83 Million	--

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic

Market Cap

$186.84 Million

Rs17.28 Billion INR

Market Cap Rank

#16896 Global

#871 in India

Share Price

Rs819.70

Change (1 day)

-0.38%

52-Week Range

Rs718.35 - Rs1070.80

All Time High

Rs1144.25